EVOLITO-LIMITED
16.4.2024 13:07:29 CEST | Business Wire | Press release
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics, and battery solutions for aerospace applications, announces the appointment of Marc Holme as CTO, as it prepares for future growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821458/en/
Marc Holme, CTO, Evolito (Photo: Business Wire)
Marc Holme joins as CTO to lead the technology development and the future roadmap of the axial-flux e-motor and propulsion product family. He has a 24-year tenure in aviation, most recently at Collins Aerospace where he was Senior Director of Engineering. Holme’s deep technical background has seen him lead multiple aircraft system electrification programs from Airbus A380 to Boeing 787, and many technology acquisition programs.
Commenting on his appointment, Marc Holme, CTO, Evolito said:
“I’m excited to join Evolito to continue the progression towards more sustainable aviation through electrification. The advanced electric motor technology that originated for the automotive market is being adapted and improved by Evolito to enable aerospace applications where weight, efficiency and safety are critical. Combined with its leading motor control electronics and battery technologies, Evolito is well positioned to reach scalable and sustainable electric aviation.”
The new C-suite hire follows a phenomenal year for the company, having received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products in December 2023. Evolito is already working with a number of OEM partners, developing motors and propulsion systems for a variety of eVTOL, Urban Air Mobility and fixed-wing applications, and expects a series of customer test flights later this year.
Dr. Chris Harris, Evolito CEO and co-founder said:
“The whole company is delighted to welcome Marc to the growing Evolito family. I’m extremely proud of what we have created here at Evolito, and our success is a reflection of our hugely talented and dedicated team, driven by a common passion for sustainable mobility. The electrification of flight is one of the most exciting market opportunities of our time, and Evolito’s innovative new technology and ability to scale means we are well positioned to meet this fast-emerging demand.”
Founded in July 2021, Evolito has grown its experienced team from 15 to over 200. It was recently awarded 2nd place in four award categories in the 2023 Best Companies100 Best Place To Work. In July 2022, Evolito acquired and later integrated Electroflight batteries into the business to offer complete propulsion solutions that are fully optimised for future aircraft applications. Amongst other partners, it works with Cranfield Aerospace Solutions who provide motor and inverters for its hydrogen aircraft demonstrator - the Fresson project.
EDITOR’S NOTES
Evolito
Evolito is making all-electric flight a reality by offering world-leading electric axial flux motors, motor control units and battery systems for the aerospace market. Evolito’s electric propulsion systems offer the highest power, torque, and energy densities in class and are inherently more robust than alternative technologies – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications. The privately-held company is based in Oxford. Evolito’s investors include B-Flexion and Oxford Science Enterprises (OSE).
Marc Holme, CTO, Evolito boasts 24 years of experience in aviation and a further 5 in automotive. Prior to joining Evolito, Holme was Senior Director Engineering at Collins Aerospace. He has also worked for UTC Aerospace Systems and Goodrich. Holme has a masters in power electronics and drives from The University of Birmingham.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416821458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
